PGE2/EP4 skeleton interoception activity reduces vertebral endplate porosity and spinal pain with low-dose celecoxib

Abstract

Skeletal interoception regulates bone homeostasis through the prostaglandin E2 (PGE2) concentration in bone. Vertebral endplates undergo ossification and become highly porous during intervertebral disc degeneration and aging. We found that the PGE2 concentration was elevated in porous endplates to generate spinal pain. Importantly, treatment with a high-dose cyclooxygenase 2 inhibitor (celecoxib, 80 mg·kg⁻¹ per day) decreased the prostaglandin E2 concentration and attenuated spinal pain in mice with lumbar spine instability. However, this treatment impaired bone formation in porous endplates, and spinal pain recurred after discontinuing the treatment. Interestingly, low-dose celecoxib (20 mg·kg⁻¹ per day, which is equivalent to one-quarter of the clinical maximum dosage) induced a latent inhibition of spinal pain at 3 weeks post-treatment, which persisted even after discontinuing treatment. Furthermore, when the prostaglandin E2 concentration was maintained at the physiological level with low-dose celecoxib, endplate porosity was reduced significantly, which was associated with decreased sensory nerve innervation and spinal pain. These findings suggest that low-dose celecoxib may help to maintain skeletal interoception and decrease vertebral endplate porosity, thereby reducing sensory innervation and spinal pain in mice.

References

[1] Ludwig C, Luthy C, Allaz AF, Herrmann FR, Cedraschi C. The impact of low back pain on health-related quality of life in old age: results from a survey of a large sample of Swiss elders living in the community. Eur. Spine J., 2018, 27: 1157-1165

[2] Tsuji S et al. Low back pain is closely associated with frailty but not with sarcopenia: Cross-sectional study of rural Japanese community-dwelling older adults. Geriatr. Gerontol. Int, 2021, 21: 54-59

[3] Rubin DI. Epidemiology and risk factors for spine pain. Neurol. Clin., 2007, 25: 353-371

[4] Samartzis D, Grivas TB. Thematic series—Low back pain. Scoliosis Spinal Disord., 2017, 12

[5] Bove SE, Flatters SJ, Inglis JJ, Mantyh PW. New advances in musculoskeletal pain. Brain Res Rev., 2009, 60: 187-201

[6] Peiro AM et al. Pharmacogenomics in pain treatment. Drug Metab. Pers. Ther., 2016, 31: 131-142

[7] Hawker GA. The assessment of musculoskeletal pain. Clin. Exp. Rheumatol., 2017, 35 Suppl 107 8-12

[8] Colloca L et al. Neuropathic pain. Nat. Rev. Dis. Prim., 2017, 3: 17002

[9] Jones MR et al. Pain in the Elderly. Curr. Pain. Headache Rep., 2016, 20

[10] Luoma K, Vehmas T, Kerttula L, Gronblad M, Rinne E. Chronic low back pain in relation to Modic changes, bony endplate lesions, and disc degeneration in a prospective MRI study. Eur. Spine J., 2016, 25: 2873-2881

[11] Ding Q et al. Cyclooxygenase-2 deficiency causes delayed ossification of lumbar vertebral endplates. Am. J. Transl. Res., 2018, 10: 718-730

[12] Munir S et al. Endplate defect is heritable, associated with low back pain and triggers intervertebral disc degeneration: a longitudinal study from TwinsUK. Spine (Philos. Pa 1976), 2018, 43: 1496-1501

[13] Jarvinen J et al. Association between changes in lumbar Modic changes and low back symptoms over a two-year period. BMC Musculoskelet. Disord., 2015, 16

[14] Brayda-Bruno M, Albano D, Cannella G, Galbusera F, Zerbi A. Endplate lesions in the lumbar spine: a novel MRI-based classification scheme and epidemiology in low back pain patients. Eur. Spine J., 2018, 27: 2854-2861

[15] Chen L et al. Lumbar vertebral endplate defects on magnetic resonance images: prevalence, distribution patterns, and associations with back pain. Spine J., 2020, 20: 352-360

[16] Bian Q et al. Excessive activation of TGFbeta by spinal instability causes vertebral endplate sclerosis. Sci. Rep., 2016, 6

[17] Wang Y, Videman T, Battie MC. ISSLS prize winner: Lumbar vertebral endplate lesions: associations with disc degeneration and back pain history. Spine (Philos. Pa 1976), 2012, 37: 1490-1496

[18] Liu Q et al. Cervical spinal instability causes vertebral microarchitecture change and vertebral endplate lesion in rats. J. Orthop. Transl., 2020, 24: 209-217

[19] Fields AJ, Liebenberg EC, Lotz JC. Innervation of pathologies in the lumbar vertebral end plate and intervertebral disc. Spine J., 2014, 14: 513-521

[20] Ni S et al. Sensory innervation in porous endplates by Netrin-1 from osteoclasts mediates PGE2-induced spinal hypersensitivity in mice. Nat. Commun., 2019, 10

[21] Park JY, Pillinger MH, Abramson SB. Prostaglandin E2 synthesis and secretion: the role of PGE2 synthases. Clin. Immunol., 2006, 119: 229-240

[22] Tomazoni SS et al. Photobiomodulation therapy is able to modulate PGE2 levels in patients with chronic non-specific low back pain: a randomized placebo-controlled trial. Lasers Surg. Med., 2021, 53: 236-244

[23] Tsuge K, Inazumi T, Shimamoto A, Sugimoto Y. Molecular mechanisms underlying prostaglandin E2-exacerbated inflammation and immune diseases. Int Immunol., 2019, 31: 597-606

[24] Lin CR et al. Prostaglandin E2 receptor EP4 contributes to inflammatory pain hypersensitivity. J. Pharm. Exp. Ther., 2006, 319: 1096-1103

[25] Southall MD, Vasko MR. Prostaglandin receptor subtypes, EP3C and EP4, mediate the prostaglandin E2-induced cAMP production and sensitization of sensory neurons. J. Biol. Chem., 2001, 276: 16083-16091

[26] Ma W, Li L, Xing S. PGE2/EP4 receptor and TRPV1 channel are involved in repeated restraint stress-induced prolongation of sensitization pain evoked by subsequent PGE2 challenge. Brain Res., 2019, 1721: 146335

[27] Chen H et al. Prostaglandin E2 mediates sensory nerve regulation of bone homeostasis. Nat. Commun., 2019, 10

[28] Mach DB et al. Origins of skeletal pain: sensory and sympathetic innervation of the mouse femur. Neuroscience, 2002, 113: 155-166

[29] Hu B et al. Sensory nerves regulate mesenchymal stromal cell lineage commitment by tuning sympathetic tones. J. Clin. Invest, 2020, 130: 3483-3498

[30] Fukuda T et al. Sema3A regulates bone-mass accrual through sensory innervations. Nature, 2013, 497: 490-493

[31] Yadav VK et al. A serotonin-dependent mechanism explains the leptin regulation of bone mass, appetite, and energy expenditure. Cell, 2009, 138: 976-989

[32] Ortuno MJ et al. Serotonin-reuptake inhibitors act centrally to cause bone loss in mice by counteracting a local anti-resorptive effect. Nat. Med, 2016, 22: 1170-1179

[33] Nakao K et al. CJ-023,423, a novel, potent and selective prostaglandin EP4 receptor antagonist with antihyperalgesic properties. J. Pharm. Exp. Ther., 2007, 322: 686-694

[34] Abdel-Magid AF. Selective EP4 antagonist may be useful in treating arthritis and arthritic pain. ACS Med Chem. Lett., 2014, 5: 104-105

[35] Qaseem A, Wilt TJ, McLean RM, Forciea MA. Noninvasive treatments for acute, subacute, and chronic low back pain: a clinical practice guideline from the american college of physicians. Ann. Intern Med, 2017, 166: 514-530

[36] Simon LS, Goodman T. NSAID-induced gastrointestinal toxicity. Bull. Rheum. Dis., 1995, 44: 1-5

[37] Soll AH, McCarthy D. NSAID-related gastrointestinal complications. Clin. Cornerstone, 1999, 1: 42-56

[38] Simon LS et al. Preliminary study of the safety and efficacy of SC-58635, a novel cyclooxygenase 2 inhibitor: efficacy and safety in two placebo-controlled trials in osteoarthritis and rheumatoid arthritis, and studies of gastrointestinal and platelet effects. Arthritis Rheum., 1998, 41: 1591-1602

[39] Silverstein FE et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA, 2000, 284: 1247-1255

[40] Bombardier C et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis VIGOR Study Group. N. Engl. J. Med., 2000, 343: 1520-1528 1522 p following 1528

[41] Bhala N et al. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. Lancet, 2013, 382: 769-779

[42] Trelle S et al. Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis. BMJ, 2011, 342: c7086

[43] Mukherjee D, Nissen SE, Topol EJ. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA, 2001, 286: 954-959

[44] Risser A, Donovan D, Heintzman J, Page T. NSAID prescribing precautions. Am. Fam. Physician, 2009, 80: 1371-1378

[45] Pergolizzi JV Jr., Raffa RB, Nalamachu S, Taylor R Jr. Evolution to low-dose NSAID therapy. Pain. Manag, 2016, 6: 175-189

[46] Pepine CJ, Gurbel PA. Cardiovascular safety of NSAIDs: additional insights after PRECISION and point of view. Clin. Cardiol., 2017, 40: 1352-1356

[47] Garner, S. et al. Celecoxib for rheumatoid arthritis. Cochrane Database Syst Rev. CD003831 (2002).

[48] Puljak L et al. Celecoxib for osteoarthritis. Cochrane Database Syst. Rev., 2017, 5: CD009865

[49] Ma W, St-Jacques B, Rudakou U, Kim YN. Stimulating TRPV1 externalization and synthesis in dorsal root ganglion neurons contributes to PGE2 potentiation of TRPV1 activity and nociceptor sensitization. Eur. J. Pain., 2017, 21: 575-593

[50] Kuisma M et al. Modic changes in vertebral endplates: a comparison of MR imaging and multislice CT. Skelet. Radio., 2009, 38: 141-147

[51] Dudli S, Fields AJ, Samartzis D, Karppinen J, Lotz JC. Pathobiology of Modic changes. Eur. Spine J., 2016, 25: 3723-3734

[52] O’Connor JP, Lysz T. Celecoxib, NSAIDs and the skeleton. Drugs Today (Barc.), 2008, 44: 693-709

[53] Oury F et al. CREB mediates brain serotonin regulation of bone mass through its expression in ventromedial hypothalamic neurons. Genes Dev., 2010, 24: 2330-2342

[54] Takeda S et al. Leptin regulates bone formation via the sympathetic nervous system. Cell, 2002, 111: 305-317

[55] Zieglgansberger W. Substance P and pain chronicity. Cell Tissue Res., 2019, 375: 227-241

[56] Cao YQ et al. Primary afferent tachykinins are required to experience moderate to intense pain. Nature, 1998, 392: 390-394

[57] Miyamoto S, Yonenobu K, Ono K. Experimental cervical spondylosis in the mouse. Spine (Philos. Pa 1976), 1991, 16: S495-S500

[58] Pang Y et al. Celecoxib aggravates atherogenesis and upregulates leukotrienes in ApoE(^−/−) mice and lipopolysaccharide-stimulated RAW264.7 macrophages. Atherosclerosis, 2019, 284: 50-58

[59] Kim JS et al. The rat intervertebral disk degeneration pain model: relationships between biological and structural alterations and pain. Arthritis Res. Ther., 2011, 13: R165

Funding

U.S. Department of Health & Human Services | National Institutes of Health (NIH)(R01 AR071432)